» Articles » PMID: 35328637

Gene Expression over Time During Cell Transformation Due to Non-Genotoxic Carcinogen Treatment of Bhas 42 Cells

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Mar 25
PMID 35328637
Authors
Affiliations
Soon will be listed here.
Abstract

The Bhas 42 cell transformation assay (Bhas 42 CTA) is the first Organization for Economic Cooperation and Development (OECD)-certificated method used as a specific tool for the detection of the cell-transformation potential of tumor-promoting compounds, including non-genotoxic carcinogens (NGTxCs), as separate from genotoxic carcinogens. This assay offers the great advantage of enabling the phenotypic detection of oncotransformation. A key benefit of using the Bhas 42 CTA in the study of the cell-transformation mechanisms of tumor-promoting compounds, including non-genotoxic carcinogens, is that the cell-transformation potential of the chemical can be detected directly without treatment with a tumor-initiating compound since Bhas 42 cell line was established by transfecting the v-Ha- gene into a mouse fibroblast cloned cell line. Here, we analyzed the gene expression over time, using DNA microarrays, in Bhas 42 cells treated with the tumor-promoting compound 12--tetradecanoylphorbol-13-acetate (TPA), and NGTxC, with a total of three repeat experiments. This is the first paper to report on gene expression over time during the process of cell transformation with only a tumor-promoting compound. Pathways that were activated or inactivated during the process of cell transformation in the Bhas 42 cells treated with TPA were related not only directly to but also to various pathways in the hallmarks of cancer.

Citing Articles

Dual-directional epi-genotoxicity assay for assessing chemically induced epigenetic effects utilizing the housekeeping TK gene.

Yamada H, Odagiri M, Yamakita K, Chiba A, Ukai A, Yasui M Sci Rep. 2025; 15(1):7780.

PMID: 40044744 PMC: 11882845. DOI: 10.1038/s41598-025-92121-6.


Assessment of the carcinogenic potential of particulate matter generated from 3D printing devices in Balb/c 3T3-1-1 cells.

Lim C, Seo D Sci Rep. 2024; 14(1):23981.

PMID: 39402095 PMC: 11473660. DOI: 10.1038/s41598-024-75491-1.


A modular strategy for the testing and assessment of non-genotoxic carcinogens.

Louekari K, Jacobs M Arch Toxicol. 2024; 98(8):2463-2485.

PMID: 38811392 PMC: 11272678. DOI: 10.1007/s00204-024-03753-y.


In Vitro Approaches to Determine the Potential Carcinogenic Risk of Environmental Pollutants.

Barguilla I, Maguer-Satta V, Guyot B, Pastor S, Marcos R, Hernandez A Int J Mol Sci. 2023; 24(9).

PMID: 37175558 PMC: 10178670. DOI: 10.3390/ijms24097851.


The Cell Transformation Assay: A Historical Assessment of Current Knowledge of Applications in an Integrated Approach to Testing and Assessment for Non-Genotoxic Carcinogens.

Colacci A, Corvi R, Ohmori K, Paparella M, Serra S, Da Rocha Carrico I Int J Mol Sci. 2023; 24(6).

PMID: 36982734 PMC: 10057754. DOI: 10.3390/ijms24065659.


References
1.
Amano T, Eishi Y, Yamada T, Uchida K, Minegishi K, Tamura T . Widespread expression of γ-glutamyl cyclotransferase suggests it is not a general tumor marker. J Histochem Cytochem. 2011; 60(1):76-86. PMC: 3283131. DOI: 10.1369/0022155411428468. View

2.
Mullen P, Yu R, Longo J, Archer M, Penn L . The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016; 16(11):718-731. DOI: 10.1038/nrc.2016.76. View

3.
Resar L, Chia L, Xian L . Lessons from the Crypt: HMGA1-Amping up Wnt for Stem Cells and Tumor Progression. Cancer Res. 2018; 78(8):1890-1897. PMC: 6435269. DOI: 10.1158/0008-5472.CAN-17-3045. View

4.
Kim G, Mercer S, Ewton D, Yan Z, Jin K, Friedman E . The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem. 2002; 277(33):29792-802. DOI: 10.1074/jbc.M201299200. View

5.
Sasaki K, Mizusawa H, Ishidate M . Isolation and characterization of ras-transfected BALB/3T3 clone showing morphological transformation by 12-O-tetradecanoyl-phorbol-13-acetate. Jpn J Cancer Res. 1988; 79(8):921-30. PMC: 5917616. DOI: 10.1111/j.1349-7006.1988.tb00056.x. View